Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer

被引:16
|
作者
Cao, Sheng [1 ,2 ]
Li, Yang [1 ,3 ]
Li, Jin [4 ,5 ]
Li, Chang-Fei [1 ]
Zhang, Wei [6 ]
Yang, Zeng-Qi [2 ]
Meng, Song-Dong [1 ]
机构
[1] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China
[2] NW A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China
[3] Sichuan Normal Univ, Coll Life Sci, Chengdu 610066, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100191, Peoples R China
[5] Beijing Tiantan Biol Prod Co Ltd, Beijing 100024, Peoples R China
[6] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100021, Peoples R China
关键词
HER2; overexpression; confocal microscopy assay; circulating tumor cells; quantitative measurement; CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; POLYMERASE-CHAIN-REACTION; BONE-MARROW; PERIPHERAL-BLOOD; GENE STATUS; IMMUNOFLUORESCENCE; THERAPY;
D O I
10.3892/or_00000651
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 analysis in circulating tumor cells (CTCs) may have clinical significance for HER2-targeted therapy as HER2-positive CTCs and disseminated tumor cells can be detected in patients with HER2-negative primary tumors who currently do not have access to HER2-targeted therapy. In this study, we performed quantitative analysis by confocal microscopy assay for evaluation of HER2 expression in individual tumor cells. HER2 testing by confocal microscopy assay exhibited high concordance with results of real-time PCR, Western blot analysis and FISH analysis. We found that there was a significant positive correlation between HER2 overexpression and gene amplification in individual CTCs, which provided validation of confocal microscopy assay for HER2 expression in CTCs. By using subsets of 10 consecutive cells (bins), we conclude that HER2 expression (3+) in CTCs predicts HER2 overexpression of tumor with high probability in breast cancer patients. These results may provide interpretive guidelines for HER2 status assay in CTCs and raise great opportunities for using CTCs as non-invasive and 'real-time' biopsy to examine and monitor the status of tumor markers.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [1] Expression of truncated HER2 receptor in circulating tumor cells (CTCs) of breast cancer patients
    Kallergi, Galaktia
    Nasias, Dimitris
    Papadaki, Maria A.
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    Agelaki, Sophia
    CANCER RESEARCH, 2012, 72
  • [2] Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer
    Chen, Chuang
    Peng, Jun
    Xia, He-Shun
    Yang, Gui-Fang
    Wu, Qjong-Shui
    Chen, Liang-Dong
    Zeng, Li-Bo
    Zhang, Zhi-Ling
    Pang, Dai-Wen
    Li, Yan
    BIOMATERIALS, 2009, 30 (15) : 2912 - 2918
  • [3] Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 "Ultra-Low" Setting: Implications for Precision Therapy in HER2-Breast Cancer
    Petricoin, Emanuel F.
    Corgiat, Brian A.
    O'Shaughnessy, Joyce
    LoRusso, Patricia
    Weinberg, Kris
    Davis, Justin
    Gawryletz, Chelsea
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Breast Cancer and HER2 Over Expression
    Devgan, Manish
    Mohan, Ankur
    Gangwar, Pallavi
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2014, 3 (05): : 395 - 398
  • [5] Quantitative PCR and HER2 testing in breast cancer
    Barberis, Massimo
    Pellegrini, Caterina
    Cannone, Maria
    Arizzi, Carmelo
    Coggi, Guido
    Bosari, Silvano
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (04) : 563 - 570
  • [6] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [8] Quantitative Assessment of HER2 Expression in Intraductal Neoplasms of the Breast
    Chan, Nay Nwe Nyein
    Zhan, Haiying
    Khaimova, Revekka
    Aung, Thazin
    Robbins, Charles
    Gaule, Patricia
    Rimm, David
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [10] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86